Detail akcie EnGene Holdings Rg online

Business Summary: enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Financial Summary: BRIEF: For the fiscal year ended 31 October 2025, enGene Holdings Inc revenues was not reported. Net loss increased from $55.1M to $117.3M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 98% to $123.2M, Canada segment loss increase of 98% to $123.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.46 to -$2.29.